Posttreatment Lymphopenia Is Associated With an Increased Risk of Redeveloping Nontuberculous Mycobacterial Lung Disease in Patients With Mycobacterium avium Complex Lung Disease

K. Furuuchi (Kiyose, Tokyo, Japan), K. Fujiwara (Kiyose, Tokyo, Japan), F. Uesugi (Kiyose, Tokyo, Japan), M. Shimoda (Kiyose, Tokyo, Japan), Y. Tanaka (Kiyose, Tokyo, Japan), T. Yoshiyama (Kiyose, Tokyo, Japan), K. Yoshimori (Kiyose, Tokyo, Japan), A. Kurashima (Kiyose, Tokyo, Japan), K. Ohta (Kiyose, Tokyo, Japan), K. Morimoto (Kiyose, Tokyo, Japan)

Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Furuuchi (Kiyose, Tokyo, Japan), K. Fujiwara (Kiyose, Tokyo, Japan), F. Uesugi (Kiyose, Tokyo, Japan), M. Shimoda (Kiyose, Tokyo, Japan), Y. Tanaka (Kiyose, Tokyo, Japan), T. Yoshiyama (Kiyose, Tokyo, Japan), K. Yoshimori (Kiyose, Tokyo, Japan), A. Kurashima (Kiyose, Tokyo, Japan), K. Ohta (Kiyose, Tokyo, Japan), K. Morimoto (Kiyose, Tokyo, Japan). Posttreatment Lymphopenia Is Associated With an Increased Risk of Redeveloping Nontuberculous Mycobacterial Lung Disease in Patients With Mycobacterium avium Complex Lung Disease. 3090

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Long-term Outcome of Pulmonary Resection for Nontuberculous Mycobacterial Pulmonary Disease
Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies
Year: 2017

Prevalence of Latent Infection with Mycobacterium Tuberculosis in Interstitial Lung Diseases Using Interferon Gamma Release Assay
Source: International Congress 2017 – Lung fibrosis: basic science
Year: 2017


The Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease in Japan
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017



Validation of the Nontuberculous Mycobacteria (NTM) Module in NTM Lung Disease
Source: International Congress 2018 – The global impact of bronchiectasis and nontuberculous mycobacteria (NTM)
Year: 2018

Mycobacterium tuberculosis Cording in Alveolar Macrophages of Tuberculosis Patients and Mycobacterial Virulence
Source: International Congress 2017 – Microbiology and laboratory techniques to monitor NTM infections
Year: 2017

Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019

Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome
Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases
Year: 2021



A First Look at the Italian Registry on Pulmonary Non-Tuberculous Mycobacteria (NTM) -IRENE
Source: Virtual Congress 2020 – Advances in cystic fibrosis: from microbiome to MRI
Year: 2020


Diagnosing Pulmonary Tuberculosis by Pooling Induced Sputum
Source: International Congress 2017 – Microbiology and laboratory techniques to monitor NTM infections
Year: 2017


Early Fever Associated with Clinical Outcomes in Patients with Coronavirus Disease 2019
Source: Virtual Congress 2021 – COVID - 19: lessons learned
Year: 2021


Risk Factors for Noninvasive Ventilation Failure in Acute Respiratory Failure with Pneumocystis Jirovecii Pneumonia in Patients without Human Immunodeficiency Virus Infection
Source: Virtual Congress 2020 – Novel findings in intensive care unit medicine: part 1
Year: 2020

Recombinant Tuberculosis Allergen in Detecting Latent Tuberculosis Infection in Adults
Source: International Congress 2018 – Tuberculosis transmission and screening strategies
Year: 2018

A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease
Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases
Year: 2021



Resistance Training Alone Improves Lung Inflammation and Respiratory Muscle Strenght but not Lung Function and Mechanics in Mid-Age Women
Source: Virtual Congress 2020 – Novel insights into exercise training
Year: 2020


Does a Tailored Intervention to Promote Adherence in Patients with Chronic Lung Disease Affect Exacerbations?
Source: International Congress 2019 – Exacerbations of airway diseases
Year: 2019

The Burden of Asymptomatic Lung Cancer
Source: International Congress 2019 – Early detection, follow-up and epidemiology of lung cancer
Year: 2019

Risk of Haemophilus Influenzae Infection in Patients with Chronic Obstructive Pulmonary Disease Using Inhaled Corticosteroids: A Cohort Study of 23,789 Outpatients.
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021


Aspergillus Lung Infections: A Seasonal Risk
Source: International Congress 2018 – Clinical challenges in respiratory infection
Year: 2018


Ventilator-Induced Lung Injury Increases Systemic Inflammation in Murine Pseudomonas Aeruginosa Pneumonia
Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment
Year: 2019

Impact of Pulmonary Hypertension on the Response to Pulmonary Rehabilitation in Obstructive Lung Disease
Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today
Year: 2019